AMGN in “America Imports the World's Drug Prices”
Amgen Inc.
Although Amgen sells biosimilars, its larger innovative-biologics franchise leaves it a net loser from lower benchmarked prices and reduced blockbuster value.
AMGN impact map — “America Imports the World's Drug Prices”
How this story travels from the headline to AMGN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading AMGN impact map…
Price history, marked with story events
Oct 20, 2025 – Oct 19, 2026 · 252 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
America Imports the World's Drug Prices
US reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
BEAR side — Although Amgen sells biosimilars, its larger innovative-biologics franchise leaves it a net loser from lower benchmarked prices and reduced blockbuster value.
Read the full America Imports the World's Drug Prices storyBull side
1 story- GLP-1 Eats Everything
AMGN in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
MariTide gives Amgen a differentiated, long-acting obesity candidate that could capture meaningful share of the expanding GLP-1 market.
Bear side
2 stories- Viewing
AMGN in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Although Amgen sells biosimilars, its larger innovative-biologics franchise leaves it a net loser from lower benchmarked prices and reduced blockbuster value.
- The Patent Cliff Sparks a Biotech Land Grab
AMGN in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Amgen faces mature-product pressure and carries greater balance-sheet constraints after using a large acquisition to replenish growth.